TY - JOUR
T1 - Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue
AU - Lapidari, Pietro
AU - Djehal, Nardjes
AU - Havas, Julie
AU - Gbenou, Arnauld
AU - Martin, Elise
AU - Charles, Cecile
AU - Dauchy, Sarah
AU - Pistilli, Barbara
AU - Cadeau, Claire
AU - Bertaut, Aurélie
AU - Everhard, Sibille
AU - Martin, Anne Laure
AU - Coutant, Charles
AU - Cottu, Paul
AU - Menvielle, Gwenn
AU - Dumas, Agnes
AU - Andre, Fabrice
AU - Michiels, Stefan
AU - Vaz-Luis, Ines
AU - Di Meglio, Antonio
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Background: Despite the questionable effectiveness of oral complementary and alternative medicine (OCAM) in relieving cancer-related symptoms, including fatigue (CRF), many patients use it aiming to improve their quality of life. We assessed factors associated with OCAM use, focusing on CRF. Methods: Women with stage I–III breast cancer (BC) were included from CANTO (NCT01993498). OCAM use was defined as taking homeopathy, vitamins/minerals, or herbal/dietary supplements. Multivariable multinomial logistic regressions evaluated associations of CRF (EORTC QLQ-C30), patient, and treatment characteristics with OCAM use. Results: Among 5237 women, 23.0% reported OCAM use overall (49.3% at diagnosis, 50.7% starting post-diagnosis), mostly homeopathy (65.4%). Mean (SD) CRF score was 27.6 (24.0) at diagnosis and 35.1 (25.3) at post-diagnosis. More intense CRF was consistently associated with OCAM use at diagnosis and post-diagnosis [adjusted odds ratio (aOR) for 10-point increase 1.05 (95% Confidence interval 1.01–1.09) and 1.04 (1.01–1.09) vs. never use, respectively]. Odds of using OCAM at diagnosis were higher among older [for 5-year increase, 1.09 (1.04–1.14)] and more educated patients [college vs. primary 1.80 (1.27–2.55)]. Women with income > 3000 [vs. < 1500 euros/month, 1.44 (1.02–2.03)], anxiety [vs. not, 1.25 (1.01–1.54)], and those receiving chemotherapy [vs. not, 1.32 (1.04–1.68)] had higher odds of using OCAM post-diagnosis. Conclusion: One-in-four patients reported use of OCAM. More severe CRF was consistently associated with its use. Moreover, older, better educated, wealthier, more anxious women, and those receiving chemotherapy seemed more prone to use OCAM. Characterizing profiles of BC patients more frequently resorting to OCAM may help deliver targeted information about its benefits and potential risks.
AB - Background: Despite the questionable effectiveness of oral complementary and alternative medicine (OCAM) in relieving cancer-related symptoms, including fatigue (CRF), many patients use it aiming to improve their quality of life. We assessed factors associated with OCAM use, focusing on CRF. Methods: Women with stage I–III breast cancer (BC) were included from CANTO (NCT01993498). OCAM use was defined as taking homeopathy, vitamins/minerals, or herbal/dietary supplements. Multivariable multinomial logistic regressions evaluated associations of CRF (EORTC QLQ-C30), patient, and treatment characteristics with OCAM use. Results: Among 5237 women, 23.0% reported OCAM use overall (49.3% at diagnosis, 50.7% starting post-diagnosis), mostly homeopathy (65.4%). Mean (SD) CRF score was 27.6 (24.0) at diagnosis and 35.1 (25.3) at post-diagnosis. More intense CRF was consistently associated with OCAM use at diagnosis and post-diagnosis [adjusted odds ratio (aOR) for 10-point increase 1.05 (95% Confidence interval 1.01–1.09) and 1.04 (1.01–1.09) vs. never use, respectively]. Odds of using OCAM at diagnosis were higher among older [for 5-year increase, 1.09 (1.04–1.14)] and more educated patients [college vs. primary 1.80 (1.27–2.55)]. Women with income > 3000 [vs. < 1500 euros/month, 1.44 (1.02–2.03)], anxiety [vs. not, 1.25 (1.01–1.54)], and those receiving chemotherapy [vs. not, 1.32 (1.04–1.68)] had higher odds of using OCAM post-diagnosis. Conclusion: One-in-four patients reported use of OCAM. More severe CRF was consistently associated with its use. Moreover, older, better educated, wealthier, more anxious women, and those receiving chemotherapy seemed more prone to use OCAM. Characterizing profiles of BC patients more frequently resorting to OCAM may help deliver targeted information about its benefits and potential risks.
KW - Cancer-related fatigue
KW - Cohort study
KW - Complementary and alternative medicine
KW - Early breast cancer
KW - Survivorship
UR - http://www.scopus.com/inward/record.url?scp=85115645608&partnerID=8YFLogxK
U2 - 10.1007/s10549-021-06394-2
DO - 10.1007/s10549-021-06394-2
M3 - Article
C2 - 34559354
AN - SCOPUS:85115645608
SN - 0167-6806
VL - 190
SP - 517
EP - 529
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 3
ER -